Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. GERD is one of the most common medical disorders, with estimates of up to 50% of adults reporting symptoms related to gastric reflux. Proton pump inhibitors (PPI) such as pantoprazole can relieve symptoms of GERD in a large proportion of patients. When refluxed stomach acidic content touches the lining of the esophagus, it causes a burning sensation in the chest or throat. This sensation is often referred to as heartburn. Some patients have symptoms of GERD without visible destruction of the tissue surface (no visible changes by endoscopic examination). The aim of the study is to evaluate the effect of pantoprazole on the complete remission of GERD. Complete remission is defined as endoscopically confirmed healing and symptom relief after a maximum of 12-week treatment period. Pantoprazole will be administered once daily in the morning. Endoscopy will be performed at the start of the study, and then as required after 4, 8, or 12 weeks. The study will provide further data on safety and tolerability of pantoprazole.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,200
Altana Pharma/Nycomed
Deutschlandsberg, Austria
Altana Pharma/Nycomed
Feldbach, Austria
Altana Pharma/Nycomed
Graz, Austria
Altana Pharma/Nycomed
Graz, Austria
Altana Pharma/Nycomed
Krems A. D. Donau, Austria
Altana Pharma/Nycomed
complete reflux disease remission rate after 8 weeks of treatment defined as symptom relief assessed by reflux questionnaire (ReQuest Trademark) and endoscopically confirmed healing.
complete reflux disease remission rates after 4, 8, and 12 weeks
time to reach first complete remission
time to reach sustained complete remission
time to reach first symptom relief that is based on the pre-defined GERD symptoms threshold of the reflux questionnaire
average symptom load above pre-defined GERD symptoms threshold
relief rates from reflux disease related complaints after 4, 8 and 12 weeks
endoscopically confirmed healing rates after 4, 8, and 12 weeks
symptom relief rates after 4, 8 and 12 weeks
influence of the H. pylori status on the complete reflux disease remission rate
influence of the H. pylori status on the symptom relief rates
influence of the H. pylori status on the endoscopically confirmed healing rates.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Lilienfeld, Austria
Altana Pharma/Nycomed
Stockerau, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
...and 69 more locations